New Bets, Wider Threats
As CAR-T therapy eyes new territory—solid tumors—and expands into autoimmune disease, other frontiers in drug development are beginning to open up. They highlight the raw promise of science, with cannabis-based agents targeting CNS and rare genetic disorders, as well as the larger responsibility to public health, including advancing non-opioid alternatives, addressing antibiotic resistance, and untangling the path to market in the still-contentious US biosimilars arena
Where is science taking the future of medicine? Pharm Exec’s 15th Annual Pipeline Report explores those possibilities ahead, with in-depth overviews of the most active, emerging—and critical—areas of therapeutic focus in biopharma RD today. As in years past, promising product candidates in each category are highlighted—the new targets, new modalities, and new technologies paving the road from basic science to potential commercial success and ultimately an impact on the wider healthcare ecosystem.
Pharm Exec would like to acknowledge Pharma Intelligence, part of Informa Group plc, for
... read more at: http://www.pharmexec.com/pharm-execs-2019-pipeline-report